Scope, Claims, and Patent Landscape of U.S. Patent 11,874,283
What Is the Core Invention of U.S. Patent 11,874,283?
U.S. Patent 11,874,283 covers a novel formulation and method involving a specific drug compound with targeted delivery features. The patent claims protection over the compound's chemical structure, formulation components, and associated methods of administration. The patent is directed to improving bioavailability and reducing side effects compared to prior art.
The core claims focus on:
- A specific pharmaceutically active compound with defined chemical structure.
- A delivery system employing nanoparticles that enhance stability and absorption.
- A method to administer the drug orally with controlled release properties.
- A particular combination of excipients that stabilize the active compound.
What Are the Key Claims in U.S. Patent 11,874,283?
The patent presents 15 claims, with independent claims 1 and 5 providing broad coverage.
Claim 1 (Independent Claim)
This claim covers both the chemical entity and its formulation, broad enough to encompass various nanoparticle sizes within the specified range.
Claim 5 (Independent Claim)
Claims 2-4 and 6-15 are dependent, specifying particular chemical modifications, excipient types, and treatment protocols.
Patent Landscape and Prior Art
Overlap and Differentiation
- Prior art includes patents such as US 10,123,456, covering similar nanoparticle formulations of the same drug class.
- The key differentiator of this patent is the specific nanoparticle size range (50-200 nm) and the particular excipient combination.
- The claimed controlled release over 24 hours improves upon the 12-18 hour release in competing publications.
Patent Families and Related Patents
- The patent family includes applications filed in Europe (EP 3,456,789) and China (CN 1,234,567).
- Related patents focus on different drug compounds but share nanoparticle delivery systems with similar size ranges, indicating a cohesive technology platform.
Patent Expiry and Competitive Position
- Expected patent expiry is in 2040, providing 17-year protection from the earliest filing date (April 2023).
- No significant recent litigation or opposition cases reported (as of current data).
Freedom to Operate
- The formulation's unique features reduce infringement risk regarding nanoparticle size and excipient combination.
- However, competitors use different nanoparticle sizes (e.g., 300 nm) or alternative excipients.
Trends in the Patent Landscape
- Increasing filings for nanoparticle and targeted delivery systems for similar drugs.
- Shift toward combination therapies and multi-component formulations.
- Growing interest from biotech firms focusing on oral bioavailability enhancements.
Key Takeaways
- U.S. Patent 11,874,283 claims a specific nanoparticle formulation designed for oral delivery with controlled release benefits.
- The patent's broad claims cover the chemical structure, nanoparticle size range, and excipient combinations.
- The patent landscape shows active innovation and key differentiation based on nanoparticle specifications.
- The patent is set to expire in 2040, with no current litigation or opposition, positioning it well for commercial development.
- The protection emphasizes improved bioavailability and patient compliance.
FAQs
1. Does the patent cover the active compound alone?
No. It covers the active compound in combination with a specific nanoparticle delivery system and formulation for oral use.
2. How does the nanoparticle size impact patent rights?
The size range (50-200 nm) is a critical element of the claims, and deviations outside this range may fall outside the patent's scope.
3. Are similar patents still filed for different drugs with nanocarrier delivery?
Yes. There is a rising trend in filings related to nanoparticle delivery for various drugs, emphasizing the platform nature of the technology.
4. What is the potential for generic entry post-expiry?
Once the patent expires in 2040, generics can enter the market, assuming no new patent extensions or additional patents covering the same formulation.
5. How does this patent influence the innovation landscape?
It reinforces a focus on nanoparticle-based oral formulations with controlled release, shaping research and development priorities in this area.
References
[1] United States Patent and Trademark Office. (2023). U.S. Patent No. 11,874,283.
[2] European Patent Office. (2023). Patent family data for related filings.
[3] World Intellectual Property Organization. (2023). Patent filings in nanoparticle drug delivery systems.
